SRC and lung adenocarcinoma: Consistently, we found that p-Casp8 reversely activated c-Src (pY416 c-Src or p-Src) via docking of phosphotyrosine 380 to the SH2 domain to restrain chemotherapy efficacy in lung adenocarcinoma (21).